• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

71
14
11
9
8

COUNTRY

5
4
4
2
2

CATEGORIES

  • 37
  • 29
  • 28
  • 21
  • 11
  • 7
  • 6
  • 5
  • 5
  • 5
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

55
60
73
173

PUBLISHED

2
11
51
173

PRODUCT TYPE

120
49
4

Search "Bayer: Performance, Products, Pipeline and Potential" returned 173 results.

PRODUCT TITLE
The Women’s Health Market Outlook to 2016 The Women’s Health Market Outlook to 2016 - Product Thumbnail Image

The Women’s Health Market Outlook to 2016

The Women’s Health Market Outlook to 2016 provides comprehensive coverage of the women’s health market, a incorporating disease overview and detailed epidemiological analyses of the major indications...

May 2011
FROM

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData...

April 2014
FROM

Bayer HealthCare AG - Strategic SWOT Analysis Review

Bayer HealthCare AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed...

May 2014
FROM

Bayer HealthCare Pharmaceuticals - Strategic SWOT Analysis Review

Bayer HealthCare Pharmaceuticals - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains...

June 2014
FROM
The Pain Market Outlook to 2016 The Pain Market Outlook to 2016 - Product Thumbnail Image

The Pain Market Outlook to 2016

The heterogeneity of pain necessitates a wide range of analgesics with different modes of action and delivery methods As such, many different classes of drugs co-exist in the pain market However, despite...

July 2011
FROM

Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential

“Big Pharma's Key Lifecycle Management Strategies: Maximizing the Market Potential ” provides key data, information and analysis on the key lifecycle management strategies implemented by pharmaceutical...

February 2010
FROM

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges”...

May 2013
FROM

Antibody Drug Conjugates Market, 2012-2023

Antibody Drug Conjugates (ADC) are a new class of biologic therapeutics These are complex molecules comprising of an antibody linked to few cytotoxin molecules through linker technology This class of...

May 2013
FROM
Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies - Product Thumbnail Image

Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies

The successful introduction of orphan products in Europe remains problematic for the developers, although they can seek to alleviate some of the issues by carefully developing a launch strategy The...

November 2011
FROM

Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lemtrada (Multiple Sclerosis) - Forecast and Market...

March 2013
FROM

Bispecific Antibody Therapeutics Market, 2013 - 2023

Antibody based therapeutics are the fastest growing segment of the drugs and biologics market There are 30 approved antibody based therapeutics available in the US and European markets since the launch...

September 2013
FROM

Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Masitinib (Multiple Sclerosis) - Forecast and Market...

March 2013
FROM

Tcelna (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Tcelna (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tcelna (Multiple Sclerosis) - Forecast and Market Analysis...

March 2013
FROM
Global Agrochemical Companies M&A, Joint Ventures, R&D Pipeline, and Strategies Global Agrochemical Companies M&A, Joint Ventures, R&D Pipeline, and Strategies - Product Thumbnail Image

Global Agrochemical Companies M&A, Joint Ventures, R&D Pipeline, and Strategies

A thought-provoking report on performance, capabilities, goals and strategies of the major competitors in the worldwide agrochemical market A strategic assessment of the competitive environment is widely...

November 2011
FROM

BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022

BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “BG-12 (Multiple Sclerosis) - Forecast and Market Analysis...

March 2013
FROM

NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022

NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “NU-100 (Multiple Sclerosis) - Forecast and Market Analysis...

March 2013
FROM

Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ocrelizumab (Multiple Sclerosis) - Forecast and...

March 2013
FROM

Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Laquinimod (Multiple Sclerosis) - Forecast and Market...

March 2013
FROM
Pipeline Insight: Endometriosis - New Therapies Near Market while More Innovative Targets Still Needed Pipeline Insight: Endometriosis - New Therapies Near Market while More Innovative Targets Still Needed - Product Thumbnail Image

Pipeline Insight: Endometriosis - New Therapies Near Market while More Innovative Targets Still Needed

Endometriosis is a common yet poorly understood gynecological disease that affects women of reproductive age. Symptoms include severe chronic pelvic pain and infertility. Endometriosis affects over...

December 2009
FROM

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions...

August 2012
FROM
Loading Indicator